PRACTICAL ASPECTS OF ADMINISTERING CYCLIN-DEPENDENT KINASES INHIBITORS: EFFICACY AND TOLERABILITY

Abstract

Although metastatic breast cancer remains an incurable disease, significant achievements have been made in this area over the recent years, allowing to convert breast cancer into a chronically controlled disease characterized by a torpid course. Patients with hormone-sensitive HER2-negative cancer are more likely to achieve this relatively favorable clinical outcome. It became possible with the development and implementation of highly effective combination treatment regimens that include recently developed inhibitors of cyclin-dependent kinases (CDK) 4 and 6. This article presents an overview of randomized clinical trials assessing the efficacy and safety of CDK4/6 inhibitors. It is shown that neutropenia is class-specific undesirable effect and characterizes all 3 drugs (palbociclib, ribociclib, abemaciclib); ribociclib therapy, in addition, is associated with hepatoand cardiotoxicity (prolongation of QTc interval); abemaciclib, in addition to neutropenia, is characterized by diarrhea and thromboembolic events.

Keywords

• metastatic breast cancer
• hormone therapy
• palbociclib
• ribociclib
• abemaciclib